Boots (company)

Boots UK Limited
	File:Boots logo.svg Logo used since 2006
Company type	Private company
Industry	Retail (health, beauty, pharmacy)
Founded	1849
Founder	John Boot
Headquarters	United Kingdom (original), headquarters moved to Zug, Switzerland in 2008, then private entity headquarters unspecified
Area served	United Kingdom, Ireland, Germany, Mexico, Thailand, China (retail stakes), Middle East and Indonesia (franchises)
Key people	Stefano Pessina (deputy chairman and involved in ownership)
Products	Health and beauty products, pharmacy services, optician and hearing care services
Number of employees	66,400 (2025)
Website	https://www.boots.com

Boots UK Limited (previously known as Boots the Chemists Limited) is a prominent British retailer specializing in health, beauty, and pharmacy services, with its primary operations centered in the United Kingdom.

The original parent company, The Boots Company plc, merged with Alliance UniChem in 2006, resulting in the formation of Alliance Boots. In 2007, private equity firms Kohlberg Kravis Roberts and Stefano Pessina took Alliance Boots private, relocating its headquarters to Switzerland—marking the first instance of a FTSE 100 firm being acquired by private equity. Walgreens purchased a 45% stake in 2012 and completed full ownership in 2014, establishing Walgreens Boots Alliance. In August 2025, Sycamore Partners finalized a $10 billion purchase of Walgreens Boots Alliance, subsequently spinning off Boots as an independent private entity called The Boots Group, which encompasses several international assets formerly under Walgreens Boots Alliance.

The Boots Group manages 3,912 outlets globally, employs around 66,400 staff members, and generates annual revenues of $23.6 billion. Its retail presence spans the UK, Ireland, Germany, Mexico, and Thailand; it also holds retail stakes in China and operates through franchises in the Middle East and Indonesia.

Ranked among the largest retailers by revenue and store number in both the UK and Ireland, Boots runs close to 2,000 shops across these regions as of December 2024. These include a range from community pharmacies to expansive health and beauty stores predominantly located on high streets and within shopping centres. The company offers an extensive selection of health and beauty merchandise alongside optician and hearing care services available both inside stores and at dedicated standalone clinics. Additionally, Boots operates an online retail platform and administers a customer loyalty scheme known as the Boots Advantage Card.

Early history

Established in 1849 by John Boot, Boots began as a herbal medicine business. Following John Boot’s death in 1860, his son Jesse Boot, then just ten years old, assisted in managing the Nottingham-based family herbal shop. The enterprise was formally incorporated as Boot and Co. Ltd in 1883 before adopting the name Boots Pure Drug Company Ltd in 1888. In 1920, Jesse Boot sold the firm to the American United Drug Company. However, due to financial difficulties during the Great Depression, control reverted to British ownership in 1933 under the guidance of John Boot’s grandson, John Boot. The company was rebranded The Boots Company Limited in 1971.

From 1898 until 1966, numerous Boots outlets provided a lending library service known as Boots Book-Lovers' Library.

During the 1960s, Boots ventured into pharmaceutical research and production, notably developing the widely-used pain relief medication Ibuprofen, created by John Nicholson and Stewart Adams. This innovation earned Boots the prestigious Queen's Award For Technical Achievement in 1987. In the following decade, Boots concentrated on Manoplax (Flosequinan), intended for treating congestive heart failure; however, safety issues resulted in its withdrawal from the market in 1993. Under investor pressure, Boots sold off its prescription drug division to BASF in 1994. Later on, the company divested the Nurofen brand to Reckitt Benckiser in 2006.

Growth was also achieved through acquisitions such as the takeover of Timothy Whites and Taylors Ltd—a chain comprising 622 stores—in 1968. International expansion included purchasing Canada’s Tamblyn Drugs chain in 1979.

Growth during the 1980s and Subsequent Years

In 1982, the firm inaugurated a production facility located in Cramlington, Northumberland. Moving into the early 1990s, Boots broadened its operations by purchasing Halfords, a retailer specializing in bicycles and automotive components, in 1991. The company marketed a variety of private label items, notably the PT400 typewriter, which was essentially a rebranded Silverette model imported from Japan. Additionally, Boots developed the Children's World superstore chain during the 1980s but divested it to Mothercare in 1996. The Halfords business was later sold off in 2002.

The establishment of Boots Opticians Ltd occurred in 1987 following the acquisitions of Clement Clarke Ltd and Curry and Paxton Ltd, positioning it as the second-largest retail optical chain within the UK. This division expanded further in 2009 by incorporating Dollond & Aitchison into its portfolio.

Boots ventured into dental services in 1998 by opening multiple dental care locations. That same year, it disposed of the Do It All DIY chain to Focus DIY. The company also explored "Wellbeing" offerings, which included treatments ranging from facials and homeopathy to laser eye surgery and Botox, supported by a dedicated television channel and website redirection. However, this approach was discontinued in 2003 as Boots chose to concentrate on its core pharmacy operations.

Towards the end of 2004, Boots divested its laser eye surgery business to Optical Express.

Alliance Boots Formation

In October 2005, then-chairman Sir Nigel Rudd announced a merger with Alliance UniChem, resulting in the creation of Alliance Boots plc. This merger was finalized on 31 July 2006.

In April 2007, private equity firm Kohlberg Kravis Roberts, together with deputy chairman Stefano Pessina, acquired Alliance Boots for £11.1 billion, taking the company private and outbidding a competing offer from Guy Hands's Terra Firma Capital Partners. This transaction represented the first instance of a FTSE 100 company being purchased by private equity. Subsequently, in June 2008, the corporate headquarters were moved to Zug, Switzerland, a relocation believed to have reduced UK tax liabilities by approximately £100 million each year.

On 1 October 2007, 'Boots the Chemists Limited' was renamed 'Boots UK Limited'. Additionally, employee management responsibilities were transferred to Boots Management Services Limited as of 1 July 2010.

No. 7 Protect & Perfect Intense Beauty Serum

Research conducted in 2007 by Professor Chris Griffiths and his team at the University of Manchester revealed that the No. 7 Protect & Perfect Intense Beauty Serum encouraged fibrillin-1 synthesis and appeared to diminish wrinkle appearance; these results were published in the British Journal of Dermatology. An independent investigation by BBC's Horizon program corroborated these positive effects, contributing to significant consumer interest.

This serum continues to be a leading product within Boots’ skincare range, maintaining strong market demand with waiting lists reportedly numbering in the tens of thousands for new releases. While some dermatologists have observed that it may not be as effective as prescription retinoids, it has nonetheless earned a respected position among over-the-counter anti-aging skincare solutions.

Homeopathic product sales

In 2009, Paul Bennett, Superintendent Pharmacist at Boots, informed the House of Commons Science and Technology Committee that the company lacked evidence validating the effectiveness of homeopathic remedies but continued to sell them to uphold consumer choice. This position attracted considerable media scrutiny. The following year, demonstrators organized a large-scale homeopathy "overdose" protest outside Boots outlets, underscoring public debate surrounding these products.

Walgreens

In June 2012, Walgreens, the leading pharmacy chain in the United States, acquired a 45% ownership stake in Alliance Boots for $6.7 billion. This transaction was intended to broaden the market reach of both brands—introducing Boots into the US market and expanding Walgreens' presence in the UK and China through Boots’ established channels. The agreement also included an option to complete a full merger within three years for an additional $9.5 billion. On 6 August 2014, Walgreens announced it would purchase the remaining 55% stake, resulting in a merger that created Walgreens Boots Alliance Inc.

In August 2012, Boots began retailing convenience food items sourced from Musgrave Group’s SuperValu chain in Ireland after concluding a trial partnership with Waitrose.

Charging NHS for unnecessary medication reviews

In April 2016, the Pharmacists' Defence Association accused Boots management of exploiting NHS funds by mandating that every store conduct medicine use reviews irrespective of actual patient necessity. The NHS reimbursed £28 per review, with a cap of 400 reviews per store annually.

Workplace pressure reports in 2016

At the same time, The Guardian published an article titled 'How Boots went Rogue', featuring insights from a pharmacist about workplace conditions and corporate financial strategies following the acquisition. Four days later, the newspaper released internal emails from pharmacists alleging pressure to compromise professional ethics to meet targets, triggering an unprecedented response volume.

Subsequent reports continued to highlight concerns regarding employee well-being and company practices. The Guardian later disclosed that a letter purportedly from an "independent pharmacist" criticizing its coverage had been altered by a company vice-president.

Following these revelations, Boots announced in June 2016 that UK operations director Simon Roberts would be stepping down.

Provision of emergency contraception

In July 2017, the British Pregnancy Advisory Service (BPAS) disclosed that Boots was selling emergency contraceptives at prices four times higher than cost and had refused invitations to join competitor pharmacy groups such as Superdrug and Tesco, both of which committed to eliminating profit on these products. Boots defended its pricing by citing frequent complaints from customers worried that lower prices might encourage "inappropriate use," a rationale campaigners denounced as "insulting and sexist."

BPAS called on consumers to boycott Boots and launched a petition demanding policy change. Subsequently, Boots’ legal representatives alleged that BPAS’s online complaint platform had incited a "torrent of abuse" directed at five senior managers and accused BPAS of encouraging harassment by identifying staff members. BPAS denied any evidence supporting these claims. In November 2017, more than 130 Labour MPs condemned Boots for failing to provide an affordable alternative as pledged by October. By January 2018, Boots confirmed it was supplying the lower-priced medication across all its branches.

During this timeframe, a price list dated May–July 2017 from Alliance Healthcare, Boots’ wholesaler and sister company, indicated that Levonelle One Step’s "Normal Retail Price inc. VAT" was £12.72.

Pharmacist suicide

On 25 October 2017, the House of Commons held a discussion concerning the mental well-being of pharmacists and the support provided by employers, with particular attention to the 2015 suicide of Boots pharmacist Alison Stamps. Boots came under scrutiny for its handling of the situation, as MP Kevan Jones read a letter from Stamps' parents accusing the company of "corporate greed" and neglecting their responsibilities.

BBC documentary and press coverage in 2018

On 8 January 2018, the BBC broadcast an Inside Out episode titled "Boots: Pharmacists under Pressure?", which brought to light three patient fatalities linked to dispensing mistakes and featured whistleblowers highlighting staff shortages. A former employee responsible for patient safety asserted that Boots required an additional annual investment exceeding £100 million in pharmacy staffing to fulfill its operational standards. Corresponding articles were published by the BBC on the same day.

Subsequently, a January 2018 report recounted a December 2017 event involving a "frazzled" pharmacist who dispensed incorrect medication, emphasizing ongoing staffing challenges.

Boots informed the BBC that no deaths related to dispensing errors had occurred after 2015. Nonetheless, in July 2018, disclosures emerged about a 2016 incident where duplicate medications were supplied to patient Richard Lee, which a coroner’s inquest linked to his death.

Overcharging the NHS for products

In February 2018, Boots was criticized for charging disproportionately high prices on low-cost products supplied to the NHS, including an instance where a moisturiser retailing below £2 was billed at over £1,500. In May 2018, The Times reported that between 2013 and 2017, Boots repeatedly charged upwards of £3,200 for a medicinal mouthwash used by chemotherapy patients, whereas an independent supplier offered the same item for approximately £93. This product was sourced from Alliance Healthcare, owned by Boots’ parent company. Walgreens Boots Alliance denied allegations of overcharging, explaining that the elevated costs were due to the bespoke nature and urgency of the orders.

Sponsorship deal

In April 2019, Boots finalized a multi-million pound/euro sponsorship agreement with the women's national football teams of England, Scotland, Wales, Northern Ireland, and the Republic of Ireland. This three-year contract encompassed key tournaments such as the 2019 FIFA Women's World Cup and UEFA Women's Euro 2021.

Rationalisation

In May 2019, Boots announced intentions to shutter more than 200 stores deemed underperforming. Further restructuring plans were revealed in July 2020, involving 4,000 job reductions alongside the closure of 48 UK optician outlets.

In November 2024, Anthony Hemmerdinger was appointed as Managing Director for Boots UK and Ireland. By December 2024, reports suggested that Sycamore Partners was preparing to acquire Walgreens Boots Alliance in early 2025.

New ownership: The Boots Group

Following Sycamore Partners’ acquisition of Walgreens Boots Alliance in August 2025, ownership transitioned to The Boots Group, a privately held UK entity. This group comprises Boots UK & Ireland, Boots Opticians, No7 Beauty Company, Alliance Healthcare Germany, Farmacias Benavides in Mexico, retail pharmacy operations in Thailand, investments within China, and franchise businesses across the Middle East and Indonesia.

Products and services

Boots provides a wide array of offerings, including:

Prescription medicines available through its pharmacy outlets
Over-the-counter medications for retail customers
Health and beauty merchandise, encompassing electrical appliances such as hairdryers and electric toothbrushes
Photography solutions, evolving from traditional film development to digital kiosk printing services
Apparel collections tailored for infants, toddlers, and expectant mothers
Food and beverage items marketed under the Boots Delicious label, featuring lunchtime options promoted with "Meal Deal" offers
Optometry services
Hearing care support
Mental health provisions introduced in 2022, featuring Depression & Anxiety Treatment accessible via their Online Doctor platform at £65 per month, which includes GP consultations and access to prescribed medication. Additional assistance is offered through "SupportRoom," delivering psychological support by text or video for £40 monthly, along with a symptom checker evaluated by mental health experts.

International operations

By 2025, The Boots Group operates a network of 3,912 stores worldwide, employs approximately 66,400 staff members, and achieves annual revenues of $23.6 billion. Its retail footprint covers the United Kingdom, Ireland, Germany, Mexico, and Thailand.

Boots-branded outlets in the Middle East are managed by the Kuwait-based franchise group Alshaya, which oversees locations in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. In Indonesia, Boots stores are operated by PT Mitra Adiperkasa Tbk.

The Boots Factory Site

Situated in Beeston near Nottingham, the Boots Factory Site encompasses multiple heritage-listed buildings. Among these are the Grade I listed factory structures D6 and D10, designed in the 1930s by Sir Owen Williams. The former fire station (D34), also crafted by Williams, holds Grade II designation. The headquarters building D90, completed in 1968 and designed by Skidmore, Owings & Merrill, is recognized as Grade II* listed.

External links

The Boots Group